Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

NEUROCRINE I Form 4 May 25, 2011	BIOSCIENC	CES INC									
FORM 4	L							-	PPROVAL		
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								N OMB Number:	3235-0287		
Check this box	x		VV d	ishingtoi	Expires:	January 31,					
if no longer subject to Section 16. Form 4 or								Estimated burden hou response	urs per		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type Respo	onses)										
1. Name and Address of Reporting Person <u>*</u> POPS RICHARD F			2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES			-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
	INC [NBIX] (Chec						еск ап аррпсаві	k all applicable)			
(3. Date of Earliest Transaction (Month/Day/Year) 05/25/2011			X_ Director 10% Owner Officer (give title Other (specify below) below)				
Filed(Month/Day/Year)					Applicable Line) _X_ Form filed by	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
CAMBRIDGE,	MA 02139						Person	whole than one R	eporting		
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned		
	ansaction Date nth/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3,	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	(D) Price	(Instr. 3 and 4)				
Reminder: Report or	n a separate line	e for each cla	ass of sec	urities bene	•	•					
•						SEC 1474 (9-02)					
	Tab					sposed of, or convertible	Beneficially Owner securities)	d			

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		′ear)	(Instr. 3 and	4)
				Code V	(A) (I	D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (1)	\$ 7.05	05/25/2011		А	15,000	06/25/2011	05/25/2018	Common Stock	15,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
I generation of the	Director	10% Owner	Officer	Other			
POPS RICHARD F ALKERMES, INC. 88 SIDNEY STREET, 2ND FLR CAMBRIDGE, MA 02139	X						
Signatures							
Margaret E. Valeur-Jensen, By Pov Attorney	wer of	05/25/2011					
<u>**</u> Signature of Reporting Person			Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents option of which 1/12th of the shares underlying the option becomes vested and exercisable on June 25, 2011, an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.